Eli Lilly and Company (LLY) 76.69 $LLY
Stocks Extend Gains as Dow Chemical Leads Materials Sector
at The Street - 7 mins ago
Stocks extend session highs by early afternoon Thursday after better-than-expected earnings from Dow Chemical boosts the basic materials sector.
MMM: 156.46 (+6.64), XLB: 44.54 (+1.08), AXP: 72.30 (-4.21), AKS: 2.67 (+0.14), LLY: 76.69 (-0.32), CTXS: 79.66 (+7.74), UA: 93.23 (-5.92), LYB: 93.99 (+2.74), EBAY: 27.54 (+3.33), BHP: 35.37 (+0.67), TXN: 57.83 (+5.93), COST: 157.20 (+1.99), MCD: 110.28 (+7.74), CAT: 71.97 (+2.30), RIO: 38.06 (+0.88), DOW: 49.54 (+2.06)
Eli Lilly Q3 Earnings, Guidance Beat On Cost Control
at Investor's Business Daily - 48 mins ago
Big pharma Eli Lilly (LLY) beat Q3 earnings expectations and raised EPS guidance Thursday, though revenue was more of a mixed bag as the firm continues to struggle with foreign exchange headwinds. Lilly made 89 cents a share excluding one-time items,...
MRK: 50.81 (+0.22), LLY: 76.69 (-0.32), BMY: 63.01 (+0.50), NVS: 92.18 (+0.59)
Eli Lilly Beats on 3Q Earnings by Wide Margin, Ups View
Arpita Dutt - Zacks Investment Research - 1 hr 54 mins ago
Eli Lilly (LLY) raised its earnings outlook after posting better-than-expected third quarter earnings.
NVO: 53.36 (-1.05), AZN: 31.00 (+0.53), ABBV: 53.33 (-0.50), LLY: 76.69 (-0.32)
Stocks Jump as Europe Rallies on ECB Stimulus Hopes
at The Street - 2 hrs 8 mins ago
Stocks extend session highs Thursday, following in the footsteps of European markets which rallied on hopes of more stimulus from the European Central Bank.
MMM: 156.46 (+6.64), AXP: 72.29 (-4.22), PYPL: 35.13 (+1.30), LLY: 76.69 (-0.32), LULU: 50.79 (-1.21), CTXS: 79.66 (+7.74), UAL: 55.71 (+1.16), UA: 93.23 (-5.92), EBAY: 27.54 (+3.33), TXN: 57.83 (+5.93), COST: 157.20 (+1.99), MCD: 110.28 (+7.74), CAT: 71.97 (+2.30), DOW: 49.54 (+2.06)
Eli Lilly (LLY) Stock Gains in Pre-Market Trading on Earnings Beat, Raised Guidance
at The Street - Thu Oct 22, 8:03AM CDT
Eli Lilly (LLY) stock is increasing in pre-market trading on Thursday, after the company announced its 2015 third quarter financial results and raised its financial outlook.
LLY: 76.69 (-0.32)
Stock Futures Rise as McDonald's Posts Surprise Beat
at The Street - Thu Oct 22, 7:42AM CDT
Stock futures are higher Thursday after better-than-expected earnings from McDonald's.
MMM: 156.46 (+6.64), AXP: 72.29 (-4.22), LLY: 76.69 (-0.32), PYPL: 35.13 (+1.30), LULU: 50.79 (-1.21), CTXS: 79.66 (+7.74), UAL: 55.71 (+1.16), UA: 93.23 (-5.92), EBAY: 27.54 (+3.33), TXN: 57.83 (+5.93), MCD: 110.28 (+7.74), COST: 157.20 (+1.99), CAT: 71.97 (+2.30), DOW: 49.54 (+2.06)
Eli Lilly (LLY) Beats on Q3 Earnings, Revenues Fall Short
Zacks Equity Research - Zacks Investment Research - Thu Oct 22, 7:00AM CDT
Eli Lilly's (LLY) third quarter earnings surpassed expectations by a wide margin.
LLY: 76.69 (-0.32)
Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
M2 - Thu Oct 22, 6:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5xdtss/breast_cancer) has announced the addition of the "Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023" report to their offering. Based on clinical phases, the breast cancer therapeutics: pipeline analysis market has been segmented into three major categories: phase I drug candidates, phase II drug candidates, and phase III drug candidates. Tabular representation for phase I drug candidates and phase II drug candidates has been provided, which summarizes information about promising drug candidates under clinical trials and associated conditions, sponsors and collaborators, primary outcome measure, time frame, and status about designated safety issue. The phase III drug candidates section is further differentiated into various key molecules that are expected to give promising results. These molecules include Palbociclib (PD-0332991) Fulvestrant, NK105, BKM120, NKTR-102, Neratinib, Olaparib, DOXIL, ABP 980, CT-P6, and Trastuzumab Emtansine Pertuzumab. Commercial analysis for all these molecules is provided by forecasting the anticipated market revenue from the expected year of commercialization until 2023. Compound annual growth rate (CAGR %) for each of these molecules is also provided for the period from the expected commercialization year to 2023. A list of recommendations has been provided for new entrants as well as existing market players to assist in taking strategic initiatives in a bid to establish a strong pipeline for breast cancer therapeutic drugs. The report also profiles major players in the breast cancer therapeutics: pipeline analysis market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., and Sanofi. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Breast Cancer Therapeutics: Pipeline Analysis, by Drugs (Phase III) Chapter 5 Recommendations Chapter 6 Company Profiles - AstraZeneca plc - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Novartis International AG - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/5x...ast_cancer
PFE: 33.10 (-0.36), AZN: 31.00 (+0.53), LLY: 76.69 (-0.32), GSK: 41.35 (+0.49), NVS: 92.18 (+0.59)
Lilly beats 3Q profit forecasts
Automated Insights - Thu Oct 22, 5:33AM CDT
INDIANAPOLIS (AP) _ Eli Lilly and Co. (LLY) on Thursday reported third-quarter net income of $799.7 million.
LLY: 76.69 (-0.32)
Lilly Reports Third-Quarter 2015 Results, Revises 2015 Financial Guidance
PR Newswire - Thu Oct 22, 5:25AM CDT
Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2015.
LLY: 76.69 (-0.32), NVS: 92.18 (+0.59)
Lilly and AstraZeneca Expand Immuno-Oncology Research Collaboration with New Combinations
PR Newswire - Thu Oct 22, 5:20AM CDT
Eli Lilly and Company (NYSE: LLY) and AstraZeneca (NYSE: AZN) today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumors.
AZN: 31.00 (+0.53), LLY: 76.69 (-0.32)
Amazon, Microsoft, McDonald's, Under Armour Earnings in Focus
at The Street - Wed Oct 21, 7:15PM CDT
Alphabet, Union Pacific and Southwest Airlines are among the many companies reporting earnings Thursday.
MMM: 156.46 (+6.64), AMZN: 567.41 (+11.64), LLY: 76.69 (-0.32), GOOG: 651.79 (+9.18), LUV: 43.89 (+2.85), UAL: 55.71 (+1.16), T: 34.08 (+0.48), UA: 93.23 (-5.92), MCD: 110.28 (+7.74), CAT: 71.97 (+2.30), MSFT: 48.80 (+1.60), DOW: 49.54 (+2.06), UNP: 97.51 (+4.10)
Biotech Stocks Slump Again on Valeant's 'Smoking Gun'
at The Street - Wed Oct 21, 3:02PM CDT
Biotech stocks were in the crossfire again on Wednesday as investors fled. But this time Hillary Clinton wasn't to blame.
KO: 43.74 (+1.55), VRX: 98.21 (-20.40), F: 15.62 (+0.21), KMB: 120.93 (+2.84), PFE: 33.10 (-0.36), IBB: 303.94 (-0.52), FCAU: 15.33 (+0.13), LLY: 76.69 (-0.32), TM: 125.38 (+1.68), BMY: 63.01 (+0.50), BA: 147.17 (+5.98), GM: 35.46 (+0.04), ABBV: 53.33 (-0.50), HMC: 33.04 (+0.34), RACE: 56.25 (+1.25)
Stocks Fall; Valeant Defends Accounting Practices
at The Street - Wed Oct 21, 2:02PM CDT
Stocks relinquish gains made earlier Wednesday as a selloff in Valeant Pharmaceuticals pressures the rest of the biotech sector.
TSLA: 213.94 (+3.85), BIIB: 279.04 (+2.70), F: 15.62 (+0.21), VRX: 98.21 (-20.40), KMB: 120.93 (+2.84), IBB: 303.94 (-0.52), TM: 125.38 (+1.68), SBUX: 61.55 (+1.02), YHOO: 31.81 (+0.69), CMG: 657.02 (-8.65), ABBV: 53.32 (-0.51), GOOGL: 682.10 (+10.30), HMC: 33.04 (+0.34), AAPL: 114.98 (+1.22), KO: 43.74 (+1.55), AMZN: 567.41 (+11.64), MU: 16.80 (+0.37), PFE: 33.10 (-0.36), LLY: 76.68 (-0.33), FCAU: 15.33 (+0.13), BMY: 63.01 (+0.50), BA: 147.16 (+5.97), WDC: 70.80 (-0.64), LRCX: 72.56 (+1.77), MCD: 110.28 (+7.74), GM: 35.46 (+0.04), KLAC: 65.09 (+1.11), RACE: 56.25 (+1.25), SNDK: 76.81 (+0.03)
Eli Lilly (LLY) Approaches New Downside Target of $75.87
Comtex SmarTrend(R) - Wed Oct 21, 1:03PM CDT
Shares of Eli Lilly (NYSE:LLY) opened today below their pivot of $78.58 and have already reached the first level of support at $76.83. Investors may be interested in a cross of the next downside pivot targets of $75.87 and $73.16.
LLY: 76.68 (-0.33)
Global HER2-Negative Breast Cancer Market 2015-2019
M2 - Wed Oct 21, 10:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3b7bbx/global) has announced the addition of the "Global HER2-Negative Breast Cancer Market 2015-2019" report to their offering. The global HER2-negative breast cancer market to grow at a CAGR of 15.94% over the period 2014-2019. The report, Global HER2-Negative Breast Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, APAC, and EMEA; it also covers the landscape of the global HER2-negative breast cancer market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. This report covers the present scenario and the growth prospects of the global HER2-negative breast cancer market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of HER2-negative breast cancer. An increase in the patient assistance programs by government organizations and vendors will also boost the market growth. These programs are customized to meet the needs of patients who are unable to afford the expensive therapies. According to the report, the market is expected to grow because of the significant unmet medical needs across the globe. There has been a growth in the demand for various drugs to treat and prevent HER2-negative breast cancer progression. The present therapies also exhibit several safety issues, which decreases patient compliance. This presents an opportunity for drug makers to develop a therapy that can treat the cancer with better efficacy and safety parameters. Further, the report states that the market growth may be hampered because of the use of premium-priced therapies. The drugs used to treat HER2-negative breast cancer, including biologic therapies, are expensive. This could lead to treatment withdrawal by patients. Based on type of drug molecule, the market is segmented as follows: - Biologics - Small molecules Based on route of administration, the market is segmented as follows: - Oral - Parenteral Key vendors - F. Hoffmann-La Roche - Novartis - Pfizer Other prominent vendors - AbbVie - AstraZeneca - BioMarin - Bristol-Myers Squibb - Eisai - Eli Lilly - Galena Biopharma - Incyte - Merck - Merck Serono - Merrimack - Nektar - Tesaro For more information visit http://www.researchandmarkets.com/research/3b7bbx/global
MRK: 50.81 (+0.22), GALE: 1.62 (-0.03), LLY: 76.68 (-0.33), BMY: 63.01 (+0.50), NVS: 92.18 (+0.59)
After Yesterday's Decline of 3.07%, Eli Lilly Offers Investors Better Value
Comtex SmarTrend(R) - Tue Oct 20, 3:51PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $77.63 to a high of $80.34. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $78.81 on volume of 7.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 76.68 (-0.33)
Eli Lilly Set to Possibly Rebound After Yesterday's Selloff of 3.07%
Comtex SmarTrend(R) - Tue Oct 20, 3:51PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $77.63 to a high of $80.34. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $78.81 on volume of 7.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 76.68 (-0.33)
Yabao Pharmaceuticals Enters Second Innovative Collaboration With Eli Lilly and Company to Develop Diabetes Treatment
Business Wire - Tue Oct 20, 9:00AM CDT
Yabao Pharmaceutical Co., Inc. (Shanghai Stock Exchange: 600351), a leading pharmaceutical company in China, today announced a second strategic collaboration for the treatment of diabetes with Eli Lilly and Company to co-develop Lilly's sodium-glucose linked transporter inhibitor (SGLT1) molecule. Lilly's SGLT1 inhibitor program has completed a Phase I study in Singapore, in addition to extensive pre-clinical development. In July 2014, Lilly and Yabao also announced the co-development of Lilly's glucokinase activator (GKA), LY2608204.
LLY: 76.68 (-0.33)
Can Eli Lilly & Co. Recover From Expensive Failures?
Cory Renauer, The Motley Fool - Motley Fool - Tue Oct 20, 7:36AM CDT
On Monday, Eli Lilly announced an abrupt end to another large phase 3 clinical trial, just as things were beginning to look up for the beleaguered drugmaker. Recently posted data from its next-generation diabetes therapy made it seem like things...
LLY: 76.68 (-0.33)
Stocks Extend Gains as Dow Chemical Leads Materials Sector
at The Street - 7 mins ago
Stocks extend session highs by early afternoon Thursday after better-than-expected earnings from Dow Chemical boosts the basic materials sector.
MMM: 156.46 (+6.64), XLB: 44.54 (+1.08), AXP: 72.30 (-4.21), AKS: 2.67 (+0.14), LLY: 76.69 (-0.32), CTXS: 79.66 (+7.74), UA: 93.23 (-5.92), LYB: 93.99 (+2.74), EBAY: 27.54 (+3.33), BHP: 35.37 (+0.67), TXN: 57.83 (+5.93), COST: 157.20 (+1.99), MCD: 110.28 (+7.74), CAT: 71.97 (+2.30), RIO: 38.06 (+0.88), DOW: 49.54 (+2.06)
Eli Lilly Q3 Earnings, Guidance Beat On Cost Control
at Investor's Business Daily - 48 mins ago
Big pharma Eli Lilly (LLY) beat Q3 earnings expectations and raised EPS guidance Thursday, though revenue was more of a mixed bag as the firm continues to struggle with foreign exchange headwinds. Lilly made 89 cents a share excluding one-time items,...
MRK: 50.81 (+0.22), LLY: 76.69 (-0.32), BMY: 63.01 (+0.50), NVS: 92.18 (+0.59)
Eli Lilly Beats on 3Q Earnings by Wide Margin, Ups View
Arpita Dutt - Zacks Investment Research - 1 hr 54 mins ago
Eli Lilly (LLY) raised its earnings outlook after posting better-than-expected third quarter earnings.
NVO: 53.36 (-1.05), AZN: 31.00 (+0.53), ABBV: 53.33 (-0.50), LLY: 76.69 (-0.32)
Stocks Jump as Europe Rallies on ECB Stimulus Hopes
at The Street - 2 hrs 8 mins ago
Stocks extend session highs Thursday, following in the footsteps of European markets which rallied on hopes of more stimulus from the European Central Bank.
MMM: 156.46 (+6.64), AXP: 72.29 (-4.22), PYPL: 35.13 (+1.30), LLY: 76.69 (-0.32), LULU: 50.79 (-1.21), CTXS: 79.66 (+7.74), UAL: 55.71 (+1.16), UA: 93.23 (-5.92), EBAY: 27.54 (+3.33), TXN: 57.83 (+5.93), COST: 157.20 (+1.99), MCD: 110.28 (+7.74), CAT: 71.97 (+2.30), DOW: 49.54 (+2.06)
Eli Lilly (LLY) Stock Gains in Pre-Market Trading on Earnings Beat, Raised Guidance
at The Street - Thu Oct 22, 8:03AM CDT
Eli Lilly (LLY) stock is increasing in pre-market trading on Thursday, after the company announced its 2015 third quarter financial results and raised its financial outlook.
LLY: 76.69 (-0.32)
Stock Futures Rise as McDonald's Posts Surprise Beat
at The Street - Thu Oct 22, 7:42AM CDT
Stock futures are higher Thursday after better-than-expected earnings from McDonald's.
MMM: 156.46 (+6.64), AXP: 72.29 (-4.22), LLY: 76.69 (-0.32), PYPL: 35.13 (+1.30), LULU: 50.79 (-1.21), CTXS: 79.66 (+7.74), UAL: 55.71 (+1.16), UA: 93.23 (-5.92), EBAY: 27.54 (+3.33), TXN: 57.83 (+5.93), MCD: 110.28 (+7.74), COST: 157.20 (+1.99), CAT: 71.97 (+2.30), DOW: 49.54 (+2.06)
Eli Lilly (LLY) Beats on Q3 Earnings, Revenues Fall Short
Zacks Equity Research - Zacks Investment Research - Thu Oct 22, 7:00AM CDT
Eli Lilly's (LLY) third quarter earnings surpassed expectations by a wide margin.
LLY: 76.69 (-0.32)
Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
M2 - Thu Oct 22, 6:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5xdtss/breast_cancer) has announced the addition of the "Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023" report to their offering. Based on clinical phases, the breast cancer therapeutics: pipeline analysis market has been segmented into three major categories: phase I drug candidates, phase II drug candidates, and phase III drug candidates. Tabular representation for phase I drug candidates and phase II drug candidates has been provided, which summarizes information about promising drug candidates under clinical trials and associated conditions, sponsors and collaborators, primary outcome measure, time frame, and status about designated safety issue. The phase III drug candidates section is further differentiated into various key molecules that are expected to give promising results. These molecules include Palbociclib (PD-0332991) Fulvestrant, NK105, BKM120, NKTR-102, Neratinib, Olaparib, DOXIL, ABP 980, CT-P6, and Trastuzumab Emtansine Pertuzumab. Commercial analysis for all these molecules is provided by forecasting the anticipated market revenue from the expected year of commercialization until 2023. Compound annual growth rate (CAGR %) for each of these molecules is also provided for the period from the expected commercialization year to 2023. A list of recommendations has been provided for new entrants as well as existing market players to assist in taking strategic initiatives in a bid to establish a strong pipeline for breast cancer therapeutic drugs. The report also profiles major players in the breast cancer therapeutics: pipeline analysis market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., and Sanofi. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Breast Cancer Therapeutics: Pipeline Analysis, by Drugs (Phase III) Chapter 5 Recommendations Chapter 6 Company Profiles - AstraZeneca plc - Eisai Co., Ltd. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Novartis International AG - Pfizer, Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/5x...ast_cancer
PFE: 33.10 (-0.36), AZN: 31.00 (+0.53), LLY: 76.69 (-0.32), GSK: 41.35 (+0.49), NVS: 92.18 (+0.59)
Lilly beats 3Q profit forecasts
Automated Insights - Thu Oct 22, 5:33AM CDT
INDIANAPOLIS (AP) _ Eli Lilly and Co. (LLY) on Thursday reported third-quarter net income of $799.7 million.
LLY: 76.69 (-0.32)
Lilly Reports Third-Quarter 2015 Results, Revises 2015 Financial Guidance
PR Newswire - Thu Oct 22, 5:25AM CDT
Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2015.
LLY: 76.69 (-0.32), NVS: 92.18 (+0.59)
Lilly and AstraZeneca Expand Immuno-Oncology Research Collaboration with New Combinations
PR Newswire - Thu Oct 22, 5:20AM CDT
Eli Lilly and Company (NYSE: LLY) and AstraZeneca (NYSE: AZN) today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumors.
AZN: 31.00 (+0.53), LLY: 76.69 (-0.32)
Amazon, Microsoft, McDonald's, Under Armour Earnings in Focus
at The Street - Wed Oct 21, 7:15PM CDT
Alphabet, Union Pacific and Southwest Airlines are among the many companies reporting earnings Thursday.
MMM: 156.46 (+6.64), AMZN: 567.41 (+11.64), LLY: 76.69 (-0.32), GOOG: 651.79 (+9.18), LUV: 43.89 (+2.85), UAL: 55.71 (+1.16), T: 34.08 (+0.48), UA: 93.23 (-5.92), MCD: 110.28 (+7.74), CAT: 71.97 (+2.30), MSFT: 48.80 (+1.60), DOW: 49.54 (+2.06), UNP: 97.51 (+4.10)
Biotech Stocks Slump Again on Valeant's 'Smoking Gun'
at The Street - Wed Oct 21, 3:02PM CDT
Biotech stocks were in the crossfire again on Wednesday as investors fled. But this time Hillary Clinton wasn't to blame.
KO: 43.74 (+1.55), VRX: 98.21 (-20.40), F: 15.62 (+0.21), KMB: 120.93 (+2.84), PFE: 33.10 (-0.36), IBB: 303.94 (-0.52), FCAU: 15.33 (+0.13), LLY: 76.69 (-0.32), TM: 125.38 (+1.68), BMY: 63.01 (+0.50), BA: 147.17 (+5.98), GM: 35.46 (+0.04), ABBV: 53.33 (-0.50), HMC: 33.04 (+0.34), RACE: 56.25 (+1.25)
Stocks Fall; Valeant Defends Accounting Practices
at The Street - Wed Oct 21, 2:02PM CDT
Stocks relinquish gains made earlier Wednesday as a selloff in Valeant Pharmaceuticals pressures the rest of the biotech sector.
TSLA: 213.94 (+3.85), BIIB: 279.04 (+2.70), F: 15.62 (+0.21), VRX: 98.21 (-20.40), KMB: 120.93 (+2.84), IBB: 303.94 (-0.52), TM: 125.38 (+1.68), SBUX: 61.55 (+1.02), YHOO: 31.81 (+0.69), CMG: 657.02 (-8.65), ABBV: 53.32 (-0.51), GOOGL: 682.10 (+10.30), HMC: 33.04 (+0.34), AAPL: 114.98 (+1.22), KO: 43.74 (+1.55), AMZN: 567.41 (+11.64), MU: 16.80 (+0.37), PFE: 33.10 (-0.36), LLY: 76.68 (-0.33), FCAU: 15.33 (+0.13), BMY: 63.01 (+0.50), BA: 147.16 (+5.97), WDC: 70.80 (-0.64), LRCX: 72.56 (+1.77), MCD: 110.28 (+7.74), GM: 35.46 (+0.04), KLAC: 65.09 (+1.11), RACE: 56.25 (+1.25), SNDK: 76.81 (+0.03)
Eli Lilly (LLY) Approaches New Downside Target of $75.87
Comtex SmarTrend(R) - Wed Oct 21, 1:03PM CDT
Shares of Eli Lilly (NYSE:LLY) opened today below their pivot of $78.58 and have already reached the first level of support at $76.83. Investors may be interested in a cross of the next downside pivot targets of $75.87 and $73.16.
LLY: 76.68 (-0.33)
Global HER2-Negative Breast Cancer Market 2015-2019
M2 - Wed Oct 21, 10:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3b7bbx/global) has announced the addition of the "Global HER2-Negative Breast Cancer Market 2015-2019" report to their offering. The global HER2-negative breast cancer market to grow at a CAGR of 15.94% over the period 2014-2019. The report, Global HER2-Negative Breast Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, APAC, and EMEA; it also covers the landscape of the global HER2-negative breast cancer market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. This report covers the present scenario and the growth prospects of the global HER2-negative breast cancer market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of HER2-negative breast cancer. An increase in the patient assistance programs by government organizations and vendors will also boost the market growth. These programs are customized to meet the needs of patients who are unable to afford the expensive therapies. According to the report, the market is expected to grow because of the significant unmet medical needs across the globe. There has been a growth in the demand for various drugs to treat and prevent HER2-negative breast cancer progression. The present therapies also exhibit several safety issues, which decreases patient compliance. This presents an opportunity for drug makers to develop a therapy that can treat the cancer with better efficacy and safety parameters. Further, the report states that the market growth may be hampered because of the use of premium-priced therapies. The drugs used to treat HER2-negative breast cancer, including biologic therapies, are expensive. This could lead to treatment withdrawal by patients. Based on type of drug molecule, the market is segmented as follows: - Biologics - Small molecules Based on route of administration, the market is segmented as follows: - Oral - Parenteral Key vendors - F. Hoffmann-La Roche - Novartis - Pfizer Other prominent vendors - AbbVie - AstraZeneca - BioMarin - Bristol-Myers Squibb - Eisai - Eli Lilly - Galena Biopharma - Incyte - Merck - Merck Serono - Merrimack - Nektar - Tesaro For more information visit http://www.researchandmarkets.com/research/3b7bbx/global
MRK: 50.81 (+0.22), GALE: 1.62 (-0.03), LLY: 76.68 (-0.33), BMY: 63.01 (+0.50), NVS: 92.18 (+0.59)
After Yesterday's Decline of 3.07%, Eli Lilly Offers Investors Better Value
Comtex SmarTrend(R) - Tue Oct 20, 3:51PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $77.63 to a high of $80.34. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $78.81 on volume of 7.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 76.68 (-0.33)
Eli Lilly Set to Possibly Rebound After Yesterday's Selloff of 3.07%
Comtex SmarTrend(R) - Tue Oct 20, 3:51PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $77.63 to a high of $80.34. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $78.81 on volume of 7.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 76.68 (-0.33)
Yabao Pharmaceuticals Enters Second Innovative Collaboration With Eli Lilly and Company to Develop Diabetes Treatment
Business Wire - Tue Oct 20, 9:00AM CDT
Yabao Pharmaceutical Co., Inc. (Shanghai Stock Exchange: 600351), a leading pharmaceutical company in China, today announced a second strategic collaboration for the treatment of diabetes with Eli Lilly and Company to co-develop Lilly's sodium-glucose linked transporter inhibitor (SGLT1) molecule. Lilly's SGLT1 inhibitor program has completed a Phase I study in Singapore, in addition to extensive pre-clinical development. In July 2014, Lilly and Yabao also announced the co-development of Lilly's glucokinase activator (GKA), LY2608204.
LLY: 76.68 (-0.33)
Can Eli Lilly & Co. Recover From Expensive Failures?
Cory Renauer, The Motley Fool - Motley Fool - Tue Oct 20, 7:36AM CDT
On Monday, Eli Lilly announced an abrupt end to another large phase 3 clinical trial, just as things were beginning to look up for the beleaguered drugmaker. Recently posted data from its next-generation diabetes therapy made it seem like things...
LLY: 76.68 (-0.33)
